Novartis’s Latest Trial Setback Sinks Stock – WSJ
Novartis’s Latest Trial Setback Sinks Stock WSJNovartis shares sink on second pipeline setback this week ReutersNovartis Sees Avidity Drug Fail in Third Setback in a Week Bloomberg.comNovartis Dealmaking Serves as Cautionary Tale for Pharma M&A WSJNovartis drops 13% on trial failure, dragging Dyne and Sarepta (NVS:NYSE) Seeking Alpha
সূত্র: মূল সংবাদসূত্র